Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.
Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.
Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).